[HTML][HTML] Diabetes dyslipidemia
JD Schofield, Y Liu, P Rao-Balakrishna, RA Malik… - Diabetes therapy, 2016 - Springer
Diabetes mellitus is associated with a considerably increased risk of premature
atherosclerotic cardiovascular disease. Intensive glycemic control has essentially failed to …
atherosclerotic cardiovascular disease. Intensive glycemic control has essentially failed to …
[HTML][HTML] Liraglutide and cardiovascular outcomes in type 2 diabetes
SP Marso, GH Daniels… - … England Journal of …, 2016 - Mass Medical Soc
Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue,
when added to standard care in patients with type 2 diabetes, remains unknown. Methods In …
when added to standard care in patients with type 2 diabetes, remains unknown. Methods In …
Mortality and cardiovascular disease in type 1 and type 2 diabetes
T Htay, K Soe, A Lopez-Perez, AHA Doan… - Current cardiology …, 2019 - Springer
Abstract Purpose of Review The aims of this review are to summarize recent data on
mortality and cardiovascular disease (CVD) in type 1 and type 2 diabetes and to determine …
mortality and cardiovascular disease (CVD) in type 1 and type 2 diabetes and to determine …
Air pollution and the heart: updated evidence from meta-analysis studies
Abstract Purpose of Review Although environmental exposure such as air pollution is
detrimental to cardiovascular disease (CVD), the effects of different air pollutants on different …
detrimental to cardiovascular disease (CVD), the effects of different air pollutants on different …
[HTML][HTML] Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus–International Task Force
S Kalra, S Bahendeka, R Sahay, S Ghosh… - Indian journal of …, 2018 - journals.lww.com
For decades, sulfonylureas (SUs) have been important drugs in the antidiabetic therapeutic
armamentarium. They have been used as monotherapy as well as combination therapy …
armamentarium. They have been used as monotherapy as well as combination therapy …
[HTML][HTML] The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses …
Y Nakatsu, H Kokubo, B Bumdelger… - International journal of …, 2017 - mdpi.com
Recent clinical studies have revealed the treatment of diabetic patients with sodium glucose
co-transporter2 (SGLT2) inhibitors to reduce the incidence of cardiovascular events. Using …
co-transporter2 (SGLT2) inhibitors to reduce the incidence of cardiovascular events. Using …
Associations of glycemic index and glycemic load with cardiovascular disease: updated evidence from meta-analysis and cohort studies
Abstract Purpose of Review Diet and lifestyle patterns are considered major contributory
factors for cardiovascular disease (CVD) and mortality. In particular, consuming a diet higher …
factors for cardiovascular disease (CVD) and mortality. In particular, consuming a diet higher …
[HTML][HTML] Drug repurposing for glioblastoma and current advances in drug delivery—a comprehensive review of the literature
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults with an
extremely poor prognosis. There is a dire need to develop effective therapeutics to …
extremely poor prognosis. There is a dire need to develop effective therapeutics to …
Haem oxygenase‐1 up‐regulation by rosiglitazone via ROS‐dependent Nrf2‐antioxidant response elements axis or PPARγ attenuates LPS‐mediated lung …
Background and Purpose Haem oxygenase‐1 (HO‐1) is induced by thiazolidinediones
including rosiglitazone and exerts anti‐inflammatory effects in various models. However, the …
including rosiglitazone and exerts anti‐inflammatory effects in various models. However, the …
[HTML][HTML] Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
J Xu, R Rajaratnam - Cardiovascular diabetology, 2017 - Springer
Patients with type 2 diabetes mellitus have a twofold increased risk of cardiovascular
mortality compared with non-diabetic individuals. There is a growing awareness that …
mortality compared with non-diabetic individuals. There is a growing awareness that …